Optimizing Denosumab Therapy in Rheumatic Diseases: Considerations for Disease Activity, Glucocorticoid Use, and Sequential Treatment
We read with great interest the article by Furukawa et al, titled "Long-Term Effectiveness and Safety of Denosumab for Osteoporosis in Patients With Rheumatic Diseases."<sup>1</sup> The authors9 comprehensive evaluation of bone mineral density (BMD) changes over 7 years in patients with rheumatic diseases (RDs) provides critical insights into the long-term efficacy and safety of denosumab in this high-risk population.
Authors
- Zhisheng Huang (ORCID: https://orcid.org/0000-0002-6406-8878)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-3474-422X)
- Jingqing Lin
- Qi Zhong
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Guangdong Provincial Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2026-03-15
- DOI
- https://doi.org/10.3899/jrheum.2025-0826
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00